Seres Therapeutics (MCRB) Current Deferred Revenue: 2016-2024
Historic Current Deferred Revenue for Seres Therapeutics (MCRB) over the last 8 years, with Jun 2024 value amounting to $7.9 million.
- Seres Therapeutics' Current Deferred Revenue rose 181.22% to $7.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.9 million, marking a year-over-year increase of 181.22%. This contributed to the annual value of $7.7 million for FY2023, which is 81.50% up from last year.
- Per Seres Therapeutics' latest filing, its Current Deferred Revenue stood at $7.9 million for Q2 2024, which was down 2.31% from $8.1 million recorded in Q1 2024.
- Seres Therapeutics' Current Deferred Revenue's 5-year high stood at $22.6 million during Q4 2020, with a 5-year trough of $2.4 million in Q1 2023.
- Its 3-year average for Current Deferred Revenue is $7.9 million, with a median of $7.8 million in 2023.
- In the last 5 years, Seres Therapeutics' Current Deferred Revenue crashed by 88.38% in 2023 and then soared by 241.29% in 2024.
- Quarterly analysis of 5 years shows Seres Therapeutics' Current Deferred Revenue stood at $22.6 million in 2020, then decreased by 25.59% to $16.8 million in 2021, then tumbled by 74.68% to $4.3 million in 2022, then spiked by 81.50% to $7.7 million in 2023, then soared by 181.22% to $7.9 million in 2024.
- Its Current Deferred Revenue stands at $7.9 million for Q2 2024, versus $8.1 million for Q1 2024 and $7.7 million for Q4 2023.